Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 13, 2007

Virium Pharmaceuticals Gains Rights to Southern Research Institute’s Oncology Compound

  • Southern Research Institute licensed rights to an oncology candidate to Virium Pharmaceuticals. In exchange, Southern Research will receive cash and stock in Virium and will hold seats on the company’s scientific advisory board and the board of directors.

    SR9025 reportedly has shown activity against certain types of leukemia and autoimmune diseases. It is a third generation, novel nucleoside analog that has completed two Phase I trials.

    “This is the first anticancer compound to be licensed after the completion of early clinical trials and we are eager to see it move through the pipeline,” says John A. Secrist, III, Ph.D., president and CEO of Southern Research.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »